Drug and Alcohol Dependence is a premier journal published by Elsevier Ireland Ltd, dedicated to the rigorous exploration and analysis of substance use disorders, including drug and alcohol dependencies. With its established history since 1975 and a remarkable convergence of research extending to 2024, the journal holds a prestigious position within the academic community, evidenced by its Q1 ranking in multiple categories, including Pharmacology, Psychiatry and Mental Health, and Toxicology for 2023. It ranks impressively among its peers, underscored by Scopus rankings of #46, #99, and #27 in key fields related to medical pharmacology and toxicology. As a non-open access title, it caters to a global readership of researchers, professionals, and students, providing them with peer-reviewed insights into critical developments and innovative methodologies in the field. The journal’s commitment to advancing knowledge and understanding of drug and alcohol dependence is essential for addressing the global challenges posed by substance use, making it a valuable resource for all stakeholders in public health and clinical practice.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE is a distinguished publication dedicated to advancing the understanding of psychiatric practice and mental health issues within a medical framework. Published by SAGE PUBLICATIONS INC, this journal has been a trusted source in the field since its inception, with its archives dating back to 1973. It offers a comprehensive exploration of psychiatric research, clinical studies, and theoretical advancements that seek to bridge the gap between psychiatry and general medicine. With an impact factor reflective of its quality and relevance, categorized in the Q3 quartile in Psychiatry and Mental Health, this journal stands as a vital resource for researchers, clinicians, and students alike. Although operating on a traditional subscription model, the extensive knowledge shared within its pages contributes significantly to ongoing discussions in psychiatric and mental health education and practice. As the field continually evolves, the INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE remains committed to fostering innovative and impactful scholarship that resonates with professionals navigating the complexities of mental health in clinical contexts.

PSYCHOLOGICAL MEDICINE is a leading journal in the field of psychiatry and psychology, published by Cambridge University Press. With its ISSN 0033-2917 and E-ISSN 1469-8978, this journal has firmly established itself as a premier platform for cutting-edge research since its inception in 1970. It consistently ranks in the top quartile for both Applied Psychology and Psychiatry and Mental Health, reflecting its exceptional impact in the field, with a 2023 Scopus ranking of #36 out of 567 in Psychiatry and Mental Health, and #21 out of 249 in Applied Psychology. The journal aims to publish comprehensive studies that explore the interplay between psychological phenomena and medical health, contributing vital insights that advance both theoretical understanding and clinical practice. Although it is not an Open Access journal, PSYCHOLOGICAL MEDICINE remains a vital resource for researchers, professionals, and students committed to the scientific investigation of mental health issues.

PSYCHIATRY RESEARCH is a leading journal published by Elsevier Ireland Ltd, dedicated to advancing the field of psychiatry and mental health through the dissemination of rigorous research. With an impressive impact factor and categorized in the top quartile (Q1) of both Biological Psychiatry and Psychiatry and Mental Health in 2023, this journal ranks 14th in the field of Medicine _ Psychiatry and Mental Health out of 567 journals, and 4th in Neuroscience _ Biological Psychiatry out of 51, showcasing its influence and quality. Since its inception in 1979, PSYCHIATRY RESEARCH has provided a platform for innovative studies, clinical trials, and comprehensive reviews aimed at understanding the complexities of mental health disorders. Although it operates under a traditional access model, the journal remains committed to making vital research available to the academic community, ensuring that both seasoned professionals and budding researchers have access to groundbreaking findings. Positioned as a hub for psychiatric research, it caters to a diverse audience including clinicians, psychologists, and students, empowering them to contribute to the evolving landscape of mental health care.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading peer-reviewed journal that serves the interdisciplinary field of neuropsychopharmacology and biological psychiatry. With an impressive impact factor in the first quartile of both Biological Psychiatry and Pharmacology categories, this journal provides a critical platform for the dissemination of cutting-edge research and innovative therapeutic approaches. Covering a broad range of topics from the molecular mechanisms underlying psychiatric disorders to advanced pharmacological interventions, it aims to foster scientific dialogue among researchers, clinicians, and students alike. The journal has been at the forefront of scientific inquiry since its inception in 1982 and continues to evolve, adapting to the ever-changing landscape of neuroscience and mental health research. With its focus on high-quality articles and a commitment to advancing the understanding of neuropsychopharmacology, this journal is essential for anyone interested in the complexities of brain function and mental health.

Trends in Psychiatry and Psychotherapy, published by ASSOC PSIQUIATRIA RIO GRANDE SUL, is a leading open-access journal dedicated to advancing the fields of psychiatry and mental health. Since its inception in 2011, this Brazilian journal has committed itself to disseminating high-quality research and innovative clinical practices, providing a platform for both established researchers and emerging voices in the field. With a notable impact factor and ranking within the Q2 quartile for both psychiatry and miscellaneous medicine categories in 2023, this journal is recognized for its significant contribution to the academic community. It serves as a vital resource for researchers, professionals, and students alike, facilitating knowledge exchange and fostering collaboration across disciplines. The open-access model ensures that cutting-edge findings are accessible to a global audience, enhancing the discourse surrounding mental health and psychiatric care. For more information and to explore current publications, please visit the journal's website.

Neuropsychopharmacology Reports is a leading open-access journal published by WILEY, dedicated to advancing the fields of clinical psychology, pharmacology, psychiatry, and mental health. Established in 2018, the journal aims to disseminate high-quality research findings, critical reviews, and innovative methodologies that elucidate the complexities of neuropsychopharmacology in enhancing mental health outcomes. With an impressive impact indicated by its Q2 rankings in several categories including Clinical Psychology and Pharmacology (medical) as of 2023, Neuropsychopharmacology Reports stands out as a vital resource for researchers, professionals, and students keen on exploring the interplay between pharmacological interventions and psychological well-being. The journal’s open-access nature ensures that critical advancements in this rapidly evolving field are readily available to a global audience, fostering collaboration and discourse among scholars and practitioners alike. Building on its indexed status with Scopus, the journal is positioned as a noteworthy contributor to ongoing discussions and developments in psychiatry and medical pharmacology.

The Journal of Dual Diagnosis, published by Routledge Journals, Taylor & Francis Ltd, is a leading interdisciplinary platform dedicated to the critical study of co-occurring mental health and substance use disorders. With its ISSN 1550-4263 and E-ISSN 1550-4271, this esteemed journal has been at the forefront of advancing research and clinical practice since its inception in 2004, and continues to serve as a vital resource until 2024. Ranked in the second quartile (Q2) in Psychiatry and Mental Health and positioned at the 64th percentile in the Scopus rankings, it emphasizes the importance of integrating care across various domains of health. Although not open access, it offers a wealth of peer-reviewed articles, case studies, and reviews suitable for researchers, practitioners, and students alike, aiming to enhance our understanding and treatment of dual diagnosis. The journal's commitment to addressing the complexities of dual disorders not only informs research but also shapes policy and clinical guidelines, making it an essential read for anyone involved in these critical areas of mental health.

Neuropsychiatric Disease and Treatment, published by DOVE MEDICAL PRESS LTD, is a prominent open access journal dedicated to advancing the field of neuropsychiatry. Since its inception in 2009, this journal has provided a platform for the dissemination of high-quality research on innovative therapies and treatments for neuropsychiatric disorders. With an impressive Q2 ranking in Psychiatry and Mental Health and a Q3 ranking in Biological Psychiatry as of 2023, it holds a reputable position within the scholarly community, reflecting its commitment to impactful research. The journal's open access model ensures widespread accessibility, fostering collaboration and dialogue among researchers, clinicians, and students worldwide. The journal accepts a variety of article types, including original research, reviews, and case studies, encompassing a range of topics from pathophysiology to therapeutic advancements. With its base in New Zealand and a Scopus rank placing it within the 69th percentile of Psychiatry and Mental Health, Neuropsychiatric Disease and Treatment is an essential resource for those dedicated to understanding and treating the complexities of neuropsychiatric conditions.

PSYCHIATRY AND CLINICAL NEUROSCIENCES is a leading journal in the fields of psychiatry and clinical neurology, published by Wiley. With a commendable impact factor and a position within the prestigious Q1 quartile across multiple relevant categories—including Medicine (Miscellaneous), Neurology, and Psychiatry and Mental Health—this journal stands out for its rigorous peer-reviewed content that addresses critical issues in mental health and neurological disorders. Established in 1933, the journal has a rich history of contributing impactful research that guides both clinical practice and academic inquiry. Although it is not an open-access journal, its high relevance is underscored by its Scopus rankings, with notable percentiles in Psychiatry and Neurology, making it a vital resource for researchers, clinicians, and students looking to stay abreast of the latest advancements. Located in the United Kingdom, PSYCHIATRY AND CLINICAL NEUROSCIENCES aims to bridge the gap between theory and practical application, fostering a comprehensive understanding of the complex interplay between mental health and neurological conditions.